These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 31429521)

  • 1. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
    Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
    Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of tumor-infiltrating lymphocytes and PD-L1 expression in esophageal squamous cell carcinoma.
    Hu J; Toyozumi T; Murakami K; Endo S; Matsumoto Y; Otsuka R; Shiraishi T; Iida S; Morishita H; Makiyama T; Nishioka Y; Uesato M; Hayano K; Nakano A; Matsubara H
    Cancer Med; 2024 Sep; 13(17):e70179. PubMed ID: 39264227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
    Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High CD8
    Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
    Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.
    Habu T; Kumagai S; Bando H; Fujisawa T; Mishima S; Kotani D; Nakamura M; Hojo H; Sakashita S; Kinoshita T; Yano T; Mitsunaga S; Nishikawa H; Koyama S; Kojima T
    J Gastroenterol; 2024 Sep; 59(9):798-811. PubMed ID: 38819498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of PD-L1 expression with CD8+ T cells and oxidative stress-related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma.
    Zhang X; Yang Y; Zhao H; Tian Z; Cao Q; Li Y; Gu Y; Song Q; Hu X; Jin M; Jiang X
    J Pathol Clin Res; 2024 Jul; 10(4):e12390. PubMed ID: 38992928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
    Chen MF; Chen PT; Chen WC; Lu MS; Lin PY; Lee KD
    Oncotarget; 2016 Feb; 7(7):7913-24. PubMed ID: 26761210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
    Sugawara K; Fukuda T; Murakami C; Oka D; Yoshii T; Amori G; Ishibashi K; Kobayashi Y; Hara H; Kanda H; Motoi N
    Cancer Sci; 2024 Aug; 115(8):2819-2830. PubMed ID: 38693726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
    Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
    Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.
    Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI
    Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.
    Yehan Z; Sheng Q; Hong Y; Jiayu L; Jun H; Juan J; Min S; Jiaxin Y; Shangzhi H; Yi W; Qifeng W; Xuefeng L; Wenwu H; Xueyan C; Yang L; Zongyao H
    Front Immunol; 2024; 15():1312380. PubMed ID: 38726002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
    Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.
    Chen K; Zhu Z; Zhang N; Cheng G; Zhang F; Jin J; Wu J; Ying L; Mao W; Su D
    Med Sci Monit; 2017 Sep; 23():4619-4632. PubMed ID: 28949934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study.
    Feng T; Li Q; Zhu R; Yu C; Xu L; Ying L; Wang C; Xu W; Wang J; Zhu J; Huang M; Xu C; Jin J; Zhang X; Lu T; Yang Y; Zhu C; Chen Q; Su D
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39209452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of neoadjuvant immunotherapy and lymphocyte subset predictors in locally advanced esophageal squamous cell carcinoma: A retrospective study.
    Wang R; Wen S; Du X; Xia J; Hu B; Zhang Y; Zhou G; Jiang F; Lu X; Zhu M; Xu X; Shen B
    Cancer Med; 2024 Sep; 13(17):e70228. PubMed ID: 39275896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma.
    Hatogai K; Fujii S; Kitano S; Kojima T; Daiko H; Yoshino T; Ohtsu A; Takiguchi Y; Doi T; Ochiai A
    Br J Cancer; 2020 Feb; 122(3):413-420. PubMed ID: 31761900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer.
    Çetin K; Kökten Ş; Sarıkamış B; Yıldırım S; Gökçe ON; Barışık NÖ; Kılıç Ü
    Breast Cancer Res Treat; 2024 May; 205(1):17-27. PubMed ID: 38273215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.